|
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation |
Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2011; 15(10): 1-329 Indexing Status Subject indexing assigned by NLM MeSH Anti-Inflammatory Agents /economics /therapeutic use; Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Arthritis, Psoriatic /drug therapy /economics; Cost-Benefit Analysis; Etanercept; Humans; Immunoglobulin G /economics /therapeutic use; Infliximab; Receptors, Tumor Necrosis Factor /therapeutic use; Recombinant Fusion Proteins /economics /therapeutic use; Treatment Outcome; Tumor Necrosis Factor-alpha /economics /therapeutic use AccessionNumber 22011000397 Date bibliographic record published 22/06/2011 |
|
|
|